Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 12;13(12):2944.
doi: 10.3390/cancers13122944.

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer

Affiliations
Review

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer

Zoran Culig. Cancers (Basel). .

Abstract

Non-steroidal anti-androgens have a major role in the treatment of non-localized prostate cancer. Interleukins are involved in the regulation of many cellular functions in prostate cancer and also modify cellular response to anti-androgens. A specific role of selected IL is presented in this review. IL-8 is a cytokine expressed in prostate cancer tissue and microenvironment and promotes proliferation and androgen receptor-mediated transcription. In contrast, IL-1 displays negative effects on expression of androgen receptor and its target genes. A subgroup of prostate cancers show neuroendocrine differentiation, which may be in part stimulated by androgen ablation. A similar effect was observed after treatment of cells with IL-10. Another cytokine which is implicated in regulation of androgenic response is IL-23, secreted by myeloid cells. Most studies on androgens and IL were carried out with IL-6, which acts through the signal transducer and activator of the transcription (STAT) factor pathway. IL-6 is implicated in resistance to enzalutamide. Activation of the STAT-3 pathway is associated with increased cellular stemness. IL-6 activation of the androgen receptor in some prostate cancers is associated with increased growth in vitro and in vivo. Molecules such as galiellalactone or niclosamide have an inhibitory effect on both androgen receptor and STAT-3 pathways.

Keywords: STAT3; androgen receptor; anti-androgens; interleukins; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Maynard J.P., Ertunc O., Kulac I., Baena-Del Valle J.A., De Marzo A.M., Sfanos K.S. IL8 expression is associated with prostate cancer aggressiveness and androgen receptor loss in primary and metastatic prostate cancer. Mol. Cancer Res. 2020;18:153–165. doi: 10.1158/1541-7786.MCR-19-0595. - DOI - PubMed
    1. Seaton A., Scullin P., Maxwell P.J., Wilson C., Pettigrew J., Gallagher R., O’Sullivan J.M., Johnston P.G., Waugh D.J.J. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cells via induction of androgen receptor expression and activation. Carcinogenesis. 2008;29:1148–1156. doi: 10.1093/carcin/bgn109. - DOI - PubMed
    1. Araki S., Omori Y., Lyn D., Singh R.K., Meinbach D.M., Sandman Y., Lokeshwar V.B., Lokeshwar B.L. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007;67:6854–6862. doi: 10.1158/0008-5472.CAN-07-1162. - DOI - PubMed
    1. MacManus C.F., Pettigrew J., Seaton A., Wilson C., Maxwell P.J., Berlingen S., Purcell C., McGurk M., Johnston P.G., Waugh D.J.J. Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol. Cancer Res. 2007;5:737–748. doi: 10.1158/1541-7786.MCR-07-0032. - DOI - PubMed
    1. Li Y., He Y., Butler W., Xu L., Chang Y., Lei K., Zhang H., Zhou Y., Gao A.C., Zhang Q., et al. Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. Sci. Transl. Med. 2019;11:eaax0428. doi: 10.1126/scitranslmed.aax0428. - DOI - PMC - PubMed

LinkOut - more resources